Resource Type

Journal Article 40

Year

2023 2

2022 5

2021 1

2020 2

2019 6

2018 3

2017 3

2016 1

2015 4

2014 1

2013 1

2012 4

2011 2

2010 4

open ︾

Keywords

acute myeloid leukemia 9

acute promyelocytic leukemia 7

leukemia 7

acute lymphoblastic leukemia 5

imatinib 3

mutation 3

Philadelphia chromosome 2

chronic myeloid leukemia 2

dasatinib 2

hematopoiesis 2

immunotherapy 2

prognosis 2

relapse 2

21) 1

RUNX1 1

ABT-199 1

AML 1

AML1-ETO 1

APL 1

B cell acute lymphoblastic leukemia 1

open ︾

Search scope:

排序： Display mode:

Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research

Jiong HU

Frontiers of Medicine 2011, Volume 5, Issue 1,   Pages 45-52 doi: 10.1007/s11684-011-0117-y

Abstract:

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia.directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemiacells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the diseasea potentially curable type of leukemia.

Keywords： acute promyelocytic leukemia     arsenic     all-trans retinoic acid     survival    

HTML PDF Collect

Predictive values of plasma TNFα and IL-8 for intracranial hemorrhage in patients with acute promyelocyticleukemia

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 909-918 doi: 10.1007/s11684-021-0890-1

Abstract: In patients with acute promyelocytic leukemia (APL), intracranial hemorrhage (ICH), if not identified

Keywords： acute promyelocytic leukemia     intracranial hemorrhage     cytokines     biomarker    

HTML PDF Collect

Current treatment strategy of acute promyelocytic leukemia

Jianqing Mi

Frontiers of Medicine 2011, Volume 5, Issue 4,   Pages 341-347 doi: 10.1007/s11684-011-0169-z

Abstract: Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML).

Keywords： acute promyelocytic leukemia     all-trans retinoic acid     arsenic trioxide    

HTML PDF Collect

analysis of plasma proteins/metabolites correlated with pathogenesis and therapeutic response in acute promyelocyticleukemia

Frontiers of Medicine doi: 10.1007/s11684-023-1022-x

Abstract: The treatment of PML/RARA+ acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenicand provides an information-rich reference data cohort for the exploratory and translational study of leukemia

Keywords： acute promyelocytic leukemia     plasma proteomics     plasma metabolomics     cross-sectional correlation network    

HTML PDF Collect

of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocyticleukemia

Xiaoling Wang,Yun Tan,Yizhen Li,Jingming Li,Wen Jin,Kankan Wang

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 420-429 doi: 10.1007/s11684-016-0478-3

Abstract: cyclin-dependent kinase inhibitors is a target of the PML/RARα oncofusion protein in leukemogenesis of acute promyelocyticleukemia (APL).

Keywords： CDKN2C     acute promyelocytic leukemia     cell cycle arrest     differentiation    

HTML PDF Collect

PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocyticleukemia

Dan Huang, Yan Yang, Jian Sun, Xiaorong Dong, Jiao Wang, Hongchen Liu, Chengquan Lu, Xueyu Chen, Jing Shao, Jinsong Yan

Frontiers of Medicine 2017, Volume 11, Issue 3,   Pages 410-422 doi: 10.1007/s11684-017-0527-6

Abstract: heterotetramer (AIIt) associated with PML/RARα fusion protein causes lethal hyperfibrinolysis in acute promyelocyticleukemia (APL), but the mechanism is unclear.To facilitate the investigation of regulatory association between ANXA2 and promyelocytic leukemia/retinoic

Keywords： annexin A2-S100A10 heterotetramer     PML/RARα fusion protein     plasmin     cell invasion     acute promyelocytic leukemia    

HTML PDF Collect

Diagnosis-related Groups (DRGs)-based payment reform to bring benefits to patient care: A case study of leukemia

Zhi-Ruo ZHANG PhD, Jian-Qing MI MD, Zhao-Jun WEN MA, Sai-Juan CHEN MD, PhD, Zhu CHEN PhD, Long-Jun GU MD, Jing-Yan TANG MD, PhD, Shu-Hong SHEN MD, PhD,

Frontiers of Medicine 2010, Volume 4, Issue 1,   Pages 8-15 doi: 10.1007/s11684-010-0018-5

Abstract: the level of reimbursement from insurance is very limited, especially for critical diseases such as leukemiaTreatments of acute promyelocytic leukemia at Rui-Jin Hospital, and childhood acute lymphoblastic leukemia

Keywords： healthcare reform     diagnosis-related groups     clinical paths     comparative effectiveness analysis     acute promyelocyticleukemia     childhood acute lymphoblastic leukemia    

HTML PDF Collect

BRD4 interacts with PML/RARα in acute promyelocytic leukemia

Qun Luo, Wanglong Deng, Haiwei Wang, Huiyong Fan, Ji Zhang

Frontiers of Medicine 2018, Volume 12, Issue 6,   Pages 726-734 doi: 10.1007/s11684-017-0604-x

Abstract: However, few studies have investigated whether BRD4 influenced acute promyelocytic leukemia (APL), andwhether BRD4 had interaction with promyelocytic leukemia-retinoic acid receptor α (PML/RARα) fusion

Keywords： BRD4     PML/RARα     APL     interaction    

HTML PDF Collect

Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives

Felicitas THOL, Arnold GANSER

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 356-362 doi: 10.1007/s11684-010-0220-5

Abstract: Acute myeloid leukemia (AML) is a very heterogeneous neoplasm of the hematopoietic stem cell.

Keywords： acute myeloid leukemia     mutations     risk stratification    

HTML PDF Collect

Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era

Haiyan He, Yang Shen, Yongmei Zhu, Saijuan Chen

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 204-211 doi: 10.1007/s11684-012-0202-x

Abstract:

We evaluated the outcomes of chronic myeloid leukemia (CML) patients in three clinical phases, namely

Keywords： imatinib     chronic myeloid leukemia     complete cytogenetic response    

HTML PDF Collect

FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 896-908 doi: 10.1007/s11684-022-0944-z

Abstract: Hence, we aimed to explore its definite role in the development of acute myeloid leukemia (AML) and emphasize

Keywords： acute myeloid leukemia     FGF13     prognosis     immune-related genes     bone marrow niches    

HTML PDF Collect

hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia

Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang

Frontiers of Medicine 2015, Volume 9, Issue 3,   Pages 304-311 doi: 10.1007/s11684-015-0400-4

Abstract: tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia

Keywords： chronic myeloid leukemia     imatinib     dasatinib     nilotinib     allogeneic hematopoietic stem cell transplantation    

HTML PDF Collect

Molecular mechanisms of leukemia-associated protein degradation

Ying-Li WU, Guo-Qiang CHEN, Hu-Chen ZHOU,

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 363-370 doi: 10.1007/s11684-010-0210-7

Abstract: Transcription factors and kinases such as retinoic acid receptor-alpha (RARα), acute myeloid leukemiaAbnormalities in these proteins may cause the dysregulation of hematopoiesis and even the occurrence of leukemia, we will summarize the recent advances in the understanding of the roles of protein degradation in leukemia

Keywords： protein degradation     leukemia     chemical biology     transcription factors     oncoprotein    

HTML PDF Collect

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Abstract:

Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutelymphoblastic leukemia (B-ALL).This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblasticleukemia with poor prognosis.

Keywords： acute lymphoblastic leukemia     early T precursor     prognosis    

HTML PDF Collect

methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia

Yuting Tan,Han Liu,Saijuan Chen

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 412-420 doi: 10.1007/s11684-015-0423-x

Abstract:

Genetic mutations are considered to drive the development of acute myeloid leukemia (AML).mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia

Keywords： preleukemic stem cell     acute myeloid leukemia     relapse     DNMT3A    

HTML PDF Collect

Title Author Date Type Operation

Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research

Jiong HU

Journal Article

Predictive values of plasma TNFα and IL-8 for intracranial hemorrhage in patients with acute promyelocyticleukemia

Journal Article

Current treatment strategy of acute promyelocytic leukemia

Jianqing Mi

Journal Article

analysis of plasma proteins/metabolites correlated with pathogenesis and therapeutic response in acute promyelocyticleukemia

Journal Article

of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocyticleukemia

Xiaoling Wang,Yun Tan,Yizhen Li,Jingming Li,Wen Jin,Kankan Wang

Journal Article

PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocyticleukemia

Dan Huang, Yan Yang, Jian Sun, Xiaorong Dong, Jiao Wang, Hongchen Liu, Chengquan Lu, Xueyu Chen, Jing Shao, Jinsong Yan

Journal Article

Diagnosis-related Groups (DRGs)-based payment reform to bring benefits to patient care: A case study of leukemia

Zhi-Ruo ZHANG PhD, Jian-Qing MI MD, Zhao-Jun WEN MA, Sai-Juan CHEN MD, PhD, Zhu CHEN PhD, Long-Jun GU MD, Jing-Yan TANG MD, PhD, Shu-Hong SHEN MD, PhD,

Journal Article

BRD4 interacts with PML/RARα in acute promyelocytic leukemia

Qun Luo, Wanglong Deng, Haiwei Wang, Huiyong Fan, Ji Zhang

Journal Article

Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives

Felicitas THOL, Arnold GANSER

Journal Article

Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era

Haiyan He, Yang Shen, Yongmei Zhu, Saijuan Chen

Journal Article

FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

Journal Article

hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia

Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang

Journal Article

Molecular mechanisms of leukemia-associated protein degradation

Ying-Li WU, Guo-Qiang CHEN, Hu-Chen ZHOU,

Journal Article

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Journal Article

methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia

Yuting Tan,Han Liu,Saijuan Chen

Journal Article